Literature DB >> 24733469

Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group.

Christopher A Czaja1, Adrah Levin2, Majid Moridani3, Jessica L Krank4, Douglas Curran-Everett5, Peter L Anderson6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24733469      PMCID： PMC4068483          DOI： 10.1128/AAC.02763-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

Review 2.  Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials.

Authors:  Sofia K Kasiakou; George J Sermaides; Argyris Michalopoulos; Elpidoforos S Soteriades; Matthew E Falagas
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

Review 3.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 4.  A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics.

Authors:  Jason A Roberts; Steven Webb; David Paterson; Kwok M Ho; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

5.  Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.

Authors:  Kyeongman Jeon; O Jung Kwon; Nam Yong Lee; Bum-Joon Kim; Yoon-Hoh Kook; Seung-Heon Lee; Young Kil Park; Chang Ki Kim; Won-Jung Koh
Journal:  Am J Respir Crit Care Med       Date:  2009-08-06       Impact factor: 21.405

6.  Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease.

Authors:  Julie Jarand; Adrah Levin; Lening Zhang; Gwen Huitt; John D Mitchell; Charles L Daley
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

7.  Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.

Authors:  H Ko; K S Cathcart; D L Griffith; G R Peters; W J Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191
  7 in total
  1 in total

Review 1.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.